J. Hashimoto

发表

Erratum to: Application of Modeling and Simulation to a Long-Term Clinical Trial: A Direct Comparison of Simulated Data and Data Actually Observed in Japanese Osteoporosis Patients Following 3-Year Ibandronate Treatment

T. Kawanishi, S. Iida, K. Nakai, 2015, Clinical Pharmacokinetics.

Application of Modeling and Simulation to a Long-Term Clinical Trial: A Direct Comparison of Simulated Data and Data Actually Observed in Japanese Osteoporosis Patients Following 3-Year Ibandronate Treatment

T. Kawanishi, S. Iida, K. Nakai, 2014, Clinical Pharmacokinetics.

Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study

Toshitaka Nakamura, Masako Ito, Masato Tobinai, 2015, Journal of Bone and Mineral Metabolism.

Additive impact of alfacalcidol on bone mineral density and bone strength in alendronate treated postmenopausal women with reduced bone mass.

D. Felsenberg, G. Armbrecht, P. Martus, 2011, Journal of musculoskeletal & neuronal interactions.

Increased Bone Mineral Density with Monthly Intravenous Ibandronate Contributes to Fracture Risk Reduction in Patients with Primary Osteoporosis: Three-Year Analysis of the MOVER Study

Toshitaka Nakamura, H. Hagino, Masato Tobinai, 2014, Calcified Tissue International.

Intermittent Ibandronate Maintains Bone Mass, Bone Structure, and Biomechanical Strength of Trabecular and Cortical Bone After Discontinuation of Parathyroid Hormone Treatment in Ovariectomized Rats

H. Tomizawa, Y. Matsumoto, K. Serizawa, 2017, Calcified Tissue International.

Treatment with the combination of ibandronate plus eldecalcitol has a synergistic effect on inhibition of bone resorption without suppressing bone formation in ovariectomized rats.

F. Bauss, S. Takeda, M. Sugimoto, 2015, Bone.

Effectiveness of monthly intravenous ibandronate injections in a real-world setting: Subgroup analysis of a postmarketing observational study

Y. Takeuchi, M. Kumagai, J. Hashimoto, 2019, Osteoporosis and sarcopenia.

Safety and effectiveness of monthly intravenous ibandronate injections in a prospective, postmarketing, and observational study in Japanese patients with osteoporosis

T. Tamura, Y. Takeuchi, J. Hashimoto, 2018, Osteoporosis and sarcopenia.

Monthly oral ibandronate 100 mg is as effective as monthly intravenous ibandronate 1 mg in patients with various pathologies in the MOVEST study

Toshitaka Nakamura, H. Hagino, Masako Ito, 2018, Journal of Bone and Mineral Metabolism.

Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis

M. Ito, H. Hagino, T. Nakamura, 2015, Osteoporosis International.

Primary leiomyoma of the ureter: a case report

T. Tsuzuki, Kaori Mori, S. Aoki, 2021, Journal of Medical Case Reports.

The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties

T. Kawanishi, S. Iida, K. Nakai, 2014, European Journal of Drug Metabolism and Pharmacokinetics.

Clinical Efficacy on Fracture Risk and Safety of 0.5 mg or 1 mg/month Intravenous Ibandronate Versus 2.5 mg/day Oral Risedronate in Patients with Primary Osteoporosis

Toshitaka Nakamura, H. Hagino, Masako Ito, 2013, Calcified Tissue International.

Higher response with bone mineral density increase with monthly injectable ibandronate 1 mg compared with oral risedronate in the MOVER study

Toshitaka Nakamura, T. Nakano, Masato Tobinai, 2016, Journal of Bone and Mineral Metabolism.

Increased Bone Mineral Density with Monthly Intravenous Ibandronate Contributes to Fracture Risk Reduction in Patients with Primary Osteoporosis: Three-Year Analysis of the MOVER Study

Toshitaka Nakamura, H. Hagino, Masato Tobinai, 2014, Calcified Tissue International.